ASH 2025: Sasp-Driven Immune Evasion Defines a Novel African Ancestry-Associated DLBCL Subtype with Distinctive Molecular and Immune Vulnerabilities African Americans with diffuse large B-cell lymphoma (DLBCL) are susceptible to cancer development at an earlier age and worse survival outcomes. Genetics…
ASH 2025: Other Cancers in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma An estimated 1 in 8 people with chronic lymphocytic leukemia (CLL) or small cell leukemia (SLL) develop another type of cancer at some point during their lifetime. This…
ASH 2025: Phase II Trial of Lenalidomide Plus Rituximab (R2) in Previously Untreated Follicular Lymphoma: 15-year Follow-Up Data from MDACC Trial Several studies have demonstrated the efficacy of lenalidomide plus rituximab, known as R2, in follicular lymphoma (FL). The long-term…
Rare Disease Day: Why Lymphoma — Though Common — Is Still Considered a Rare Cancer Each year on February 28th, Rare Disease Day shines a global spotlight on conditions affecting relatively small patient populations — diseases that often struggle for…
The U.S. Food and Drug Administration (FDA) Approves Acalabrutinib with Venetoclax for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) February 20, 2025 – On February 20, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved acalabrutinib (Calquence, AstraZeneca)…
World Cancer Day: Uniting Research, Care, and Hope for People With Lymphoma In 2022, the International Agency for Research on Cancer at the World Health Organization (WHO) documented nearly 20 million new cancer cases worldwide. In the year 2050, the WHO projects that there will be over 35…
The Lymphoma Research Foundation is pleased to announce Anita Kumar, MD of Memorial Sloan Kettering Cancer Center and Sílvia Beà, PhD of August Pi i Sunyer Biomedical Research Institute (IDIBAPS) and Hospital Clínic de Barcelona, to the Executive Committee of its international Mantle Cell Lymphoma Consortium (MCLC).
The Lymphoma Research Foundation is pleased to announce that Madhu Namburi of Hillsborough, CA, Managing Director and Co-Lead of Creation Strategy at General Catalyst, has been elected to its Board of Directors.
The Lymphoma Research Foundation is pleased to announce that John Roussel of Scottsdale, AZ, a lymphoma survivor and accomplished business executive, has joined its Board of Directors.
The U.S. Food and Drug Administration (FDA) Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma December 5, 2025 – On December 5, 2025, the U.S. Food and Drug Administration (FDA) announced it has approved lisocabtagene maraleucel (Breyanzi, Juno…
